LEO 90105 Ointment in Japanese Subjects With Psoriasis

NCT ID: NCT01422434

Last Updated: 2025-03-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 676 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-07-31
• Study Completion Date: 2012-04-30

Brief Summary

The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.

Detailed Description

LEO 90105 ointment contains both calcipotriol and betamethasone dipropionate. It has been approved for the treatment of psoriasis in more than 60 centres, including most European countries, the US, China, Korea and Taiwan. This trial will investigate its safety and efficacy in the treatment of Japanese subjects with psoriasis.

Conditions

Psoriasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

LEO 90105 ointment

LEO 90105 ointment applied once daily for 4 weeks.

Group Type: ACTIVE_COMPARATOR

LEO 90105 = calcipotriol + betamethasone dipropionate

Intervention Type: DRUG

Applied once daily for 4 weeks.

Dovonex® ointment

Applied twice daily for 4 weeks.

Group Type: ACTIVE_COMPARATOR

Dovonex® = calcipotriol

Intervention Type: DRUG

Applied twice daily for 4 weeks.

Rinderon® - DP ointment

Applied once daily for 4 weeks

Group Type: ACTIVE_COMPARATOR

Rinderon® - DP = betamethasone dipropionate

Intervention Type: DRUG

Applied once daily for 4 weeks.

Interventions

LEO 90105 = calcipotriol + betamethasone dipropionate

Applied once daily for 4 weeks.

Intervention Type: DRUG

Dovonex® = calcipotriol

Applied twice daily for 4 weeks.

Intervention Type: DRUG

Rinderon® - DP = betamethasone dipropionate

Applied once daily for 4 weeks.

Intervention Type: DRUG

Other Intervention Names

LEO 90105 = Dovobet/Daivobet/Taclonex

Eligibility Criteria

Inclusion Criteria

• Subjects having understood and signed a written informed consent form prior to any study related procedures being carried out.
• Japanese subjects.
• 20 years of age or above.
• Either sex.
• Clinical diagnosis of psoriasis vulgaris amenable to topical treatment, involving arms and/or trunk and/or legs.
• A minimum m-PASI (Modified Psoriasis Area and Severity Index) score for extent of 2 in at least one body region (i.e.

psoriasis affecting at least 10% of arms, and/or 10% of trunk, and/or 10% of legs).

• Psoriasis vulgaris on the trunk/limbs (excluding psoriasis on the genitals/skin folds) of not more than 30% body surface area (BSA).
• A target lesion of a minimum of 5 cm at its longest axis and preferably not located on an elbow or knee, scoring at least 3 for each of redness, thickness and scaliness, and at least 10 in total by the physician's assessment of severity of the target lesion - A physician's global assessment of disease severity of psoriasis on trunk/limbs of mild, moderate, severe or very severe.
• Females of childbearing potential must have a negative result for a urine pregnancy test at Day 0 (Visit 1) and must agree to use an adequate method of birth control, as judged by the (sub)investigator, during the study. The contraceptive method should have started an adequate amount of time before the pregnancy test, which is dependent on the partic-ular method used and as judged by the (sub)investigator, and must continue for at least 1 week after the last application of study medication. A female is defined as not of child-bearing potential if she is postmenopausal (12 months with no menses without an alter-native medical cause) or surgically sterile (tubal ligation/section, hysterectomy or bilateral ovariectomy).

Exclusion Criteria

• Systemic use of biological treatments with a potential effect on psoriasis vulgaris within the following time periods prior to randomisation:
• etanercept, adalimumab, infliximab - 3 months
• ustekinumab - 4 months
• other products - 3 months/5 half-lives (whichever is longer).
• Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immu-nosuppressants such as ciclosporin and methotrexate) within 4 weeks prior to randomi-sation (use of inhaled and nasal corticosteroids is allowed, use of systemic antihistamines is allowed).
• Psoralen plus ultraviolet light A (PUVA) therapy, ultraviolet light B (UVB) therapy or ultraviolet light A (UVA) therapy within 4 weeks prior to randomisation.
• Topical treatment of psoriasis on area(s) to be treated with study medication within 2 weeks prior to randomisation (use of emollients is allowed during this 2-week period, but not after randomisation).
• Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D ana-logues (e.g. calcipotriol, tacalcitol, maxacalcitol), or potent or very potent World Health Organisation (WHO) group III or IV corticosteroids within 2 weeks prior to randomisation.
• Topical treatment of scalp psoriasis with vitamin D analogues (e.g. calcipotriol, tacalcitol, maxacalcitol), or very potent WHO group IV corticosteroids within 2 weeks prior to randomisation.
• Topical treatment of conditions other than psoriasis with vitamin D analogues (e.g. calcipotriol, tacalcitol, maxacalcitol), or potent or very potent WHO group III or IV cor-ticosteroids within 2 weeks prior to randomisation.
• Planned initiation of, or changes in, concomitant medication that may affect psoriasis vulgaris (e.g., beta-blockers, antimalaria drugs, lithium and Angiotensin Converting Enzyme (ACE) inhibitors) during the study.
• Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis.
• Patients with any of the following disorders (a) or symptoms (b) present on the area(s) to be treated with study medication: (a) viral (e.g., herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae, ichthyosis, acne rosacea, ulcers, burns, frostbite, wounds, or (b) fragility of skin veins..
• Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the trunk/limbs.
• Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial sunlight (including tanning booths, sun lamps, etc) during the study.
• Known or suspected disorders of calcium metabolism associated with hypercalcaemia, or albumin-corrected serum calcium above the reference range from the sample taken at the Washout/Screening Visit.
• Known or suspected severe renal insufficiency, severe hepatic disorders or severe heart disease.
• Known or suspected hypersensitivity to any components of the investigational products.
• Clinical signs or symptoms of Cushing's disease or Addison's disease
• Current participation in any other interventional clinical study.
• Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the 4 weeks prior to randomisation, or longer if the class of substance requires a longer washout as defined in exclusion criterion number 1 for biological treatments.
• Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
• Patients suspected of being unable to comply with the study protocol, e.g. due to alcoholism, drug dependence or psychotic state.
• Previous randomisation in this study.
• Hospitalised patients.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Quintiles, Inc.

INDUSTRY

Sponsor Role: collaborator

LEO Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Akira Ozawa, MD, Professor

Role: PRINCIPAL_INVESTIGATOR

Tokai University School of Medicine

Locations

Tokai University School of Medicine

Isehara, Kanagawa, Japan

Countries

Japan

Related Links

https://www.leopharmatrials.com/en

Clinical Trials at LEO Pharma

Other Identifiers

MCB 0903

Identifier Type: -

Identifier Source: org_study_id